PRL and breast carcinoma: This soluble isoform has been characterized in human breast cancer cell lines and seemingly functions as a regulatory mechanism for the bioavailability and signaling of extrapituitary PRL, which is why it is also known as “PRL binding protein” in the extracellular domain [76,77,78].